Filgrastim Biosimilars Market Size is predicted to expand with a 8.5% CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
Myeloid growth factor therapy has become the standard therapy for the treatment of neutropenia. The myeloid-specific cytokine G-CSF (granulocyte-colony stimulating factor) is the primary growth factor that increases neutrophil production. The human G-CSF gene was transduced and incorporated into Escherichia coli through recombinant DNA technology, formed drug is known as ‘filgrastim’. Filgrastim is G-CSF that stimulates the bone marrow to produce more neutrophils. The drug was developed by Amgen and marketed under the trade name Neupogen. It was approved in the U.S. by Food Drug and Administration in February 1991. Neupogen is approved for various indications, such as febrile neutropenia. It is indicated to reduce the recovery time of neutrophils and the duration of fever following chemotherapy treatment of patients suffering from acute myeloid leukemia. For the patient who are undergoing myeloablative chemotherapy in nonmyeloid malignancies, filgrastim reduces the duration of neutropenia and neutropenia-related clinical sequelae. In addition, it is used as a stem cell mobilizer and for the treatment of cyclic‚ genital‚ or idiopathic neutropenia.
The patents on Neupogen expired in the US in December 2013 and in Europe in 2006. The entry of filgrastim biosimilar into the market such as Zarzio (Sandoz), Nufil (Biocon), Grastofil (Apotex) and many more have boosted the growth of the filgrastim biosimilar market. Growing demand for biosimilar and increase in demand for cost effective treatment in low and medium-income countries further drives the growth of the filgrastim biosimilar market during the forecast period. Moreover, approximately half of cancer patients receiving chemotherapy experience some type of neutropenia, thus increase the demand for filgrastim biosimilars. However, stringent regulatory process for the approval of biosimilar and complicated manufacturing process is major restrain for the growth of the global filgrastim biosimilar market.
The global filgrastim market is segmented on the basis of application, distribution channel, and geography. On the basis of application, the global filgrastim market is segmented into febrile neutropenia, genital neutropenia, idiopathic neutropenia, and many more. An increase in the incidence of cancer patients undergoing chemotherapy has boosted the growth of the market. Based on distribution channel, the global filgrastim market is segmented into online pharmacy, hospital pharmacy and retail pharmacy. Hospital pharmacy is a major contributor in terms of revenue to the market due to increase in a number of hospital visits and hospital stays.
At the regional level, the global filgrastim biosimilar market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In terms of revenue, North America followed by Europe is a major contributor to the global filgrastim biosimilar market. This is partly because of increased government initiatives for cost-effective treatment and an increase in demand for biosimilars. Furthermore, a strong clinical pipeline and increasing research and drug development activities propel the growth of the market in these regions. Asia Pacific is the third promising revenue contributor which is expected to grow at rapid pace in the upcoming year. Countries such as Japan, India, and China are major contributors to this market and are identified as most lucrative for this market. Emerging and huge population base countries such as China and India offer tremendous market opportunities.
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 8.5% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Application, By Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; South Korea; South East Asia |
|
Competitive Landscape |
Aryogen Biopharma, Cadila Pharmaceutical, Claris Life Sciences, Dr Reddy’s Laboratories, Intas Biopharmaceuticals, Adello Biologics, Hospira(Pfizer), Genova Biopharmaceuticals (Emcure), Teva Pharmaceutical Industries, Sandoz, and others |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Filgrastim Biosimilars Market Snapshot
Chapter 4. Global Filgrastim Biosimilars Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
4.9. Clinical Trial/Pipeline Analysis
Chapter 5. Market Segmentation 1: By Application Estimates & Trend Analysis
5.1. By Application & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Application:
5.2.1. Febrile neutropenia
5.2.2. Genital neutropenia
5.2.3. Idiopathic neutropenia
5.2.4. Others
Chapter 6. Market Segmentation 2: By Distribution Channel Estimates & Trend Analysis
6.1. By Distribution Channel & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Distribution Channel:
6.2.1. Hospital Pharmacy
6.2.2. Retail Pharmacy
6.2.3. Online Pharmacy
Chapter 7. Filgrastim Biosimilars Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Filgrastim Biosimilars Market revenue (US$ Million) estimates and forecasts By Application, 2021 - 2034
7.1.2. North America Filgrastim Biosimilars Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2021 - 2034
7.1.3. North America Filgrastim Biosimilars Market revenue (US$ Million) estimates and forecasts by country, 2021 - 2034
7.2. Europe
7.2.1. Europe Filgrastim Biosimilars Market revenue (US$ Million) By Application, 2021 - 2034
7.2.2. Europe Filgrastim Biosimilars Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2021 - 2034
7.2.3. Europe Filgrastim Biosimilars Market revenue (US$ Million) by country, 2021 - 2034
7.3. Asia Pacific
7.3.1. Asia Pacific Filgrastim Biosimilars Market revenue (US$ Million) By Application, 2021 - 2034
7.3.2. Asia Pacific Filgrastim Biosimilars Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2021 - 2034
7.3.3. Asia Pacific Filgrastim Biosimilars Market revenue (US$ Million) by country, 2021 - 2034
7.4. Latin America
7.4.1. Latin America Filgrastim Biosimilars Market revenue (US$ Million) By Application, (US$ Million)
7.4.2. Latin America Filgrastim Biosimilars Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2021 - 2034
7.4.3. Latin America Filgrastim Biosimilars Market revenue (US$ Million) by country, (US$ Million) 2021 - 2034
7.5. Middle East & Africa
7.5.1. Middle East & Africa Filgrastim Biosimilars Market revenue (US$ Million) By Application, (US$ Million)
7.5.2. Middle East & Africa Filgrastim Biosimilars Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2021 - 2034
7.5.3. Middle East & Africa Filgrastim Biosimilars Market revenue (US$ Million) by country, (US$ Million) 2021 - 2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Aryogen Biopharma
8.2.2. Cadila Pharmaceutical
8.2.3. Claris Life Sciences
8.2.4. Dr Reddy’s Laboratories
8.2.5. Intas Biopharmaceuticals
8.2.6. Adello Biologics
8.2.7. Hospira(Pfizer)
8.2.9. Gennova Biopharmaceuticals
8.2.10. Teva Pharmaceutical Industries
8.2.11. Sandoz
8.2.12. Other Prominent Players
Global Filgrastim Biosimilars Market Outlook By Application
Global Filgrastim Biosimilars Market Outlook By Distribution Channel
Global Filgrastim Biosimilars Market Outlook By Region
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
